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ABSTRACT:
Over the past few years, significant advances have occurred in both our 
understanding of the complexity of signal transduction pathways as well as the 
isolation of specific inhibitors which target key components in those pathways. 
Furthermore critical information is being accrued regarding how genetic mutations 
can affect the sensitivity of various types of patients to targeted therapy. Finally, 
genetic mechanisms responsible for the development of resistance after targeted 
therapy are being discovered which may allow the creation of alternative therapies 
to overcome resistance. This review will discuss some of the highlights over the past 
few years on the roles of key signaling pathways in various diseases, the targeting 
of signal transduction pathways and the genetic mechanisms governing sensitivity 
and resistance to targeted therapies.  
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Mutations Alter the Activity of the Ras/Raf/MEK/
ERK and PI3K/PTEN/Akt/mTOR pathways.
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/
mTOR pathways are often activated by mutations within 
individual components of these pathways, as well as the 
aberrant activation of upstream growth factor receptors. 
The genetic basis of sensitivity and resistance to various 
small molecule inhibitors which target these pathways as 
well a comprehensive list of small molecule inhibitors 
as a well as their use in clinical trials have recently been 
published [1-7]. 
Predicting Sensitivity to Small Molecule 
Inhibitors. 
Extensive panels of human cell lines have been 
examined for mutations in genes implicated in cancer 
as well as for their sensitivity to various inhibitors and 
chemotherapeutic drugs commonly used to treat cancers 
[8,9]. 
The cell lines were intensively interrogated by 
expression profiling, chromosome copy number, deep 
sequencing, biostatistical and systems analyses. Both 
studies indicated that sensitivity to inhibitors was often 
linked with genetic mutations at key elements in the 
Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and some 
other pathways. Sensitivity to MEK and Raf inhibitors 
was often investigated in these studies. Sensitivity to the 
B-Raf inhibitor PLX4720 was highly associated with 
particular mutations at BRAF (V600E). Sensitivity to 
MEK inhibitors was shown to be associated with BRAF, 
NRAS as well as PTEN, PTPN5, SPRY2, DUSP4, DUSP6 
mutations and to a lesser extent mutations at KRAS. 
Sensitivity to MEK inhibitors in NRAS mutant lines was 
linked with aryl hydrocarbon receptor (AHR) expression 
[9].
Mutation of BRAF or RAS can contribute to the 
pathogenesis of many cancers, including, melanoma and 
colo-rectal cancer [10]. BRAF mutations have also been 
implicated in the pathogenesis of papillary thyroid cancer 
[11]. 
Mutation of BRAF and KRAS can result in aberrant 
c-Myc and SIRT1 protein deacetylase expression in the 
colorectal cancer [12].  Mutations at KRAS which result in 
increased mutant Ras activity can interact with increased 
Wnt expression in lung cancer and lead to a worse 
prognosis as the tumors arise at an increased incidence 
and tumors which are also larger [13]. Interesting it was 
observed that in those tumors where there was increased 
KRAS and Wnt activities they had a distinct phenotype 
which was similar to embryonic progenitors found in the 
developing lung, consistent with the previously described 
effects of the Wnt pathway on developmental processes.
Novel Targets Interacting with the Ras/Raf/MEK/
ERK Pathway.
Novel upstream Shc regulators such as the multiple 
copies in T-cell malignancy 1 (MCT-1) gene have been 
recently described which may become an important 
therapeutic target as MCT-1 is co-activated with Shc gene 
in human carcinomas and knockdown of MCT-1 enhances 
apoptotic cell death [14]. 
The CDC28 protein kinase regulatory subunit 1B 
(CKS1B) gene is involved in multiple myeloma (MM). 
There is an inverse correlation between CKS1B expression 
and survival and it may be a novel therapeutic target 
[15]. Recently it was shown that CKS1B activates both 
the Raf/MEK/ERK and STAT3 pathways and promotes 
drug resistance [16]. Targeting CKS1B may be a novel 
approach to treat certain cancers.
Advances in Our Understanding and Targeting of 
the Ras/Raf/MEK/ERK and PI3K/PTEN/mTOR 
Pathways.
Effective inhibitors specific for many of the key 
components of the Ras/Raf/MEK/ERK/MNK, Ras/PI3K/
PTEN/mTOR and other pathways have been developed. 
These pathways are often implicated in therapeutic 
resistance and interact with many pathways. [17-23]. 
Ras inhibitors have been examined in many studies 
including clinical trials. However the results so far have 
not been encouraging. Salirasib (Farnesythiosalycilic acid, 
FTS) is a Ras inhibitor. It has recently been demonstrated 
that FTS treatment of immuno-competent mice with 
subcutaneous or intracranial brain tumors resulted in 
a favorable antitumor environment [24]. The authors 
observed an increase in regulatory T-cells which altered 
the tumor microenviroment and preventing the resistance 
of the tumor cells to destruction by the immune system.
BRAF inhibitors have been shown to be effective 
in the treatment of melanomas. One of the first described 
Raf inhibitors, Sorafenib, has been shown to inhibit 
many targets, including VEGFR, PDGFR and Raf. It is 
approved for treatment of hepatocellular carcinoma (HCC) 
where there are few effective therapeutic approaches 
[25]. The mechanism of actions of sorafenib have been 
further elucidated and it has been determined to alter the 
expression of many genes in HCC [26]. A recent genomic 
analysis indicated that sorafenib significantly altered 
expression levels of 826 and 2011 transcripts in HepG2 
and Huh7 cells, respectively. The affected genes whose 
expression were upregulated in response to sorafenib 
treatment were determined to be involved in angiogenesis, 
apoptosis, transcription regulation, signal transduction, 
protein biosynthesis and modification, In contrast, 
genes which were determined to be downregulated after 
sorafenib treatment were involved in cell cycle control, 
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DNA replication recombination and repair, cell adhesion, 
metabolism and transport.  Each sorafenib-treated HCC 
cell line displayed specificity in the expression and activity 
of crucial factors involved in hepatocarcinogenesis.
The p21-activated protein kinase 1 (PAK1) kinase 
also interacts with the Ras/Raf/MEK/ERK and the PI3K/
PTEN/Akt/mTOR cascades. PAK signaling molecules 
are downstream effectors of Rho family GTPase and 
interact with both Raf and Akt. PAK inhibitors have 
been developed [27]. Interestingly, IPA3 inhibits the 
proliferation of melanoma and colorectal cancer cells with 
mutations at KRAS or NRAS better, than those containing 
mutations at BRAF. Treatment of cells with IPA3 or 
ectopic expression of DN PAK1 sensitized cell with RAS 
mutations to the B-Raf inhibitor GDC-0897 or the MEK 
inhibitor ZD6244.
Neurofibromin is a GTP-ase activating protein 
(GAP) which is mutated in neurofibromatosis patients and 
is considered a tumor suppressor.  Neurofibromin normally 
can regulate cell motility often via the Ras/Raf/MEK/ERK 
cascade by an interaction of the Ras GTPase-activating 
protein-related domain (GRD) present on Neurofibromin. 
Neurofibromin can also regulate Rho-dependent (Ras-
independent) event by activating LIM kinase 2 (LIMK2). 
LIMK2 can phosphorylates and inactivates cofilin (a 
key protein involved in actin-depolymerization factor). 
Finally, the pre-GRD domain present on Neurofibromin 
can interact with Rac1 GTPase, which activate the P21 
activated kinase 1 (PAK1)-LIMK1-cofilin pathway. 
T56-LIMKi is a novel inhibitor that was isolated by 
molecular modeling that suppressed LIMK1/2 kinase 
activities which blocked the phosphorylation of cofilin and 
disrupted actin structure and prevented effects associated 
with tumorigenicity. The combined effect of the Ras 
inhibitor Salirasib and T56-LIMKi on cell proliferation 
were examined and synergistic effects were observed [28]. 
The PIM kinases can also interact with the EGFR/
Ras/Raf/MEK/ERK pathway and certain PIM kinase 
inhibitors will induce the MIG6 gene which encodes 
a suppressor of EGFR signaling. These PIM specific 
inhibitors (M-110 and SGI-1776) suppress ERK activation 
in prostate cancer cells. Moreover synergistic effects were 
observed when the PIM inhibitors were combined with 
the EGFR inhibitor Gefitinib. These results indicate that 
the efficacy of EGFR inhibitors may be improved by PIM 
inhibitors [29]. 
Ras and other transformed cells often become 
addicted to autophagy. Targeting certain Ras-addicted cells 
with autophagy inhibitors (chloroquine and the derivative 
hydroxychloroquine) may prove to be an effective 
therapeutic approach [30]. 
Rationale for Targeting Multiple Points in Ras/
Raf/MEK ERK Pathway or Multiple Pathways.
An emerging concept in cancer therapy is the 
targeting of multiple points in a single signaling pathway. 
It has been proposed that targeting of both Raf and MEK 
or Raf and ERK may be useful in certain cancer therapies 
[31]. The concept of targeting both Raf and MEK is 
especially true with BRAF inhibitors and melanoma which 
contain mutations at BRAFV600E due to the negative 
feedback elicited by downstream ERK which suppresses 
the sensitivity of the cells to signaling induced by growth 
factors and Ras activity is low [32]. In these cells the 
mutant BRAF protein functions as a monomer. The Raf 
inhibitors suppress the activity of the BRAF monomers 
but not dimers. Inhibiting the BRAFV600E protein by the 
BRAF inhibitors inhibits the BRAFV600E protein which 
suppresses the normal negative ERK-mediated feedback 
of this pathway. However, this results in reactivation of 
ligand-dependent signal transduction and increased Ras 
activity and induces generation of Raf-inhibitor resistant 
Raf dimers and activation of MEK and downstream ERK. 
Thus combined Raf and MEK inhibitor treatment may 
become effective anti-cancer approach. Targeting both 
MEK and mTOR is a method to target melanoma which 
often have mutations at BRAF and increased activation of 
the PI3K/PTEN/Akt/mTORC1 pathway [33]. The Ras/
Raf/MEK/ERK and PI3K/PTEN/Akt/mTORC1 pathways 
are regulated by extensive crosstalk, occurring at different 
levels. In cancer, transactivation of the alternate pathway 
is a frequent “escape” mechanism. Thus combined 
inhibition of both pathways may achieve synergistic 
antitumor activity. In the M14 melanoma model, 
simultaneous inhibition of both MEK and mTORC1 
achieved synergistic effects at suboptimal concentrations.
Advances in Targeting Anti-Apoptotic Molecules 
which are Regulated by Ras/Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR Pathways.
The effects of combining MEK and Bcl-2 inhibitors 
on AML cells has been investigated [34]. Anti-apoptotic 
proteins such as Bcl-2, Bcl-XL and Mcl-1 are key 
therapeutic targets in human cancer. The mechanisms of 
actions the Bcl-2 inhibitor ABT-737 have been further 
elucidated [35]. This Bcl-2 inhibitor suppresses Bcl-2 
and Bcl-XL but not Mcl-1. ABT-737 treatment results in 
activation of the Raf/MEK/ERK cascade and downstream 
Mcl-1 in AML cells. The MEK inhibitor PD0325901 
suppresses Mcl-1 expression. Combining PD0325901 with 
ABT-737 resulted in synergistic killing of AML-derived 
cell lines, primary AML blasts and the CD34+, CD38-
, CD123+ population which is enriched in progenitor/
stem cells. These studies suggest a novel and effective 
therapeutic strategy for patients with AML.
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Treatment of AML cells with ABT-737 and PI3K/
mTOR inhibitors (BEZ235 or PI-103) resulted in a 
synergistic response in AML cells, but importantly not 
in normal CD34+ cells [36]. This synergy was shown 
to result from inhibition of Bcl-2 and Bcl-XL and the 
effects of PI3K/mTOR inhibitors were shown to be 
GSK-3 and Bim dependent. The PI3K/mTOR inhibitors 
downregulated Mcl-1 but increased Bim binding to Bcl-
2/Bcl-XL. Knock-down of GSK-3alpha/beta prevented 
Mcl-1 downregulation and decreased apoptosis induced 
by PI3K/mTOR inhibitors. Combining PI3K/Akt/mTOR 
inhibitors with BH3-mimetics may be an approach to 
treat AML especially in those patients who exhibit Akt 
activation [37]. 
Advances in Targeting Cancer Initiating Cells.
The Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/
mTOR, Wnt/beta-catenin, Notch, Hedgehog and other 
pathways are being shown to play key roles in cancer 
initiating cells (CICs) and leukemia initiating cells (LIC). 
Deregulated expression of oncogenes such as Raf-1 
have been associated with drug resistance, epithelial to 
mesenchymal transition and CIC survival [38]. Following 
metastatic dissemination, cancer cells often re-activate 
certain epithelial properties through mesenchymal to 
epithelial transition (MET) to establish neoplastic lesions 
at secondary sites. The molecular mechanisms regulating 
MET remain elusive. Recently MET has been examined in 
estrogen-receptor alpha positive (ERalpha+) MCF-7 breast 
cancer cells which overexpress activated Raf-1 and are 
more resistant to the chemotherapeutic drug doxorubicin 
than parental MCF-7 cells. Constitutive expression of 
activated Raf-1 induced HER-2/Neu overexpression and 
lead to distant metastases in xenografts. The development 
of distant metastases in xenograft models was linked to 
activation of the MET pathway as the cells expressed 
reduced expression of EMT inducer genes (TGFB2, 
TWIST1 and FOXC1) and overexpression of BMB7, 
CXCR7 and early growth response (EGR) family of 
transcription factors. 
The mitotic kinase Aurora-A promotes metastases 
by inducing EMT transition in ERalpha+ MCF-7 breast 
cancer cells which expressed constitutively-active Raf-
1 [39]. Constitutive expression of activated Raf-1 in 
MCF-7 cells induced stabilization and accumulation 
of Aurora-A mitotic kinase. This drove the transition 
from an epithelial to a highly invasive mesenchymal 
phenotype. This transition resulted in reduced expression 
of ERalpha, HER-2/Neu over-expression, and loss 
of CD24 surface receptor (CD24-/low). Importantly, 
expression of key EMT markers and upregulation of the 
stemness gene SOX2 was linked to acquisition of stem 
cell-like properties. The cells had an increased ability to 
form mammospheres in vitro and tumor self-renewal in 
vivo.  Moreover, the aberrant Aurora-A kinase activity 
induced phosphorylation and nuclear translocation of 
SMAD5, suggesting a novel interplay between Aurora-A 
and SMAD5 signaling pathways which may be important 
in the development of EMT, stemness and ultimately 
tumor progression.  Pharmacologic or molecular inhibition 
of Aurora-A kinase activity restored a CD24+ epithelial 
phenotype. This phenotype was associated with restored 
ERalpha expression, down-regulation of HER-2/Neu, 
inhibition of EMT and impaired self-renewal ability and 
suppression of metastases. Thus mitotic kinase Aurora-A 
is a promising therapeutic target to selectively eliminate 
highly invasive cancer cells. 
Advances in Elucidation of Roles of the PI3K/
PTEN/Akt/mTOR Pathway in Oncogenesis.
The PI3K pathway has recently been shown 
to be important in c-Myc expression in Burkitt’s 
lymphomagenesis in germinal center B cells [40]. The 
PI3K pathway is also an emerging target for mantle cell 
lymphoma as this cascade is upregulated in this cancer 
[41]. Disruption of PTEN and p53 activity specifically in 
the thyroid has recently been shown to result in murine 
models of anaplastic thyroid carcinomas [42]. These 
models could be important for the development of 
approaches to target human thyroid carcinomas. The PI3K 
pathway is important in many cancer including gliomas 
often due to aberrant PTEN expression. Recently it was 
show that reduction of PIK3CA or PIK3RA expression 
impeded proliferation, migration, and invasion in 
glioblastoma multiforme cells [43]. In contrast to PI3K-
alpha, PI3K-beta is oncogenic in its WT configuration 
if it is overexpressed.  PI3K-beta acts like an oncogenic 
mutant of  PI3K-alpha [44]. PI3K-delta has been shown 
to have roles in BCR-ABL-mediated chronic lymphocytic 
leukemia (CLL) by suppressing BCR signaling [45]. 
Elevated PI3K signaling has been detected in certain 
breast cancer subtypes and is believed to drive their 
abnormal proliferation [46]. Novel lipid phosphatases 
have been shown to be important in regulation of this 
pathway.  Inositol polyphosphate 4-phosphatase type II 
(INPP4B), is  tumor suppressor in implicated in many 
cancers such as prostate, breast, and ovarian cancers 
and also potentially in leukemia [47]. Akt has recently 
been shown to be an important molecule in regulation 
of homologous recombination and genetic stability in 
hereditary and sporadic breast cancers [48]. 
Advances in Targeting the PI3K/PTEN/Akt/
mTOR Pathway.
The PI3K/PTEN/Akt/mTOR pathway is also 
involved in drug resistance, sensitivity to therapy and 
metastasis [49-58]. PIK3CA mutations may act as driver 
mutations in certain cancers responsible for metastasis 
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[59]. Novel PI3K-alpha inhibitors have been isolated and 
they inhibit metastasis [60]. Most PI3K inhibitors are 
cytostatic rather than cytotoxic and it has been questioned 
whether treatment with a single PI3K inhibitor will be 
effective [61]. 
There have been many recent advances in the 
development of inhibitors which target this pathway. One 
of the key developments is in dual PI3K/mTOR inhibitors. 
Waldenstrom’s macroglobulinemia proliferates, in part, in 
response to aberrant PI3K/Akt activity. The dual PI3K/
Akt inhibitor NVP-BEZ235 suppresses the growth of the 
Waldenstrom’s anemia cells as well as has effects on the 
tumor microenvironment [62]. 
The PI3K/Akt/mTOR signaling network is activated 
in acute leukemias of both myelogenous and lymphoid 
lineage, where it correlates with poor prognosis and 
enhanced drug-resistance. Treatment of AML and ALL 
with dual PI3K/mTOR inhibitors has been shown to be 
more effective than treatment with rapamycin which 
blocks mTORC1 but not mTORC2 [63]. The dual PI3K/
mTOR inhibitors suppressed the rapamycin-resistant 
phosphorylation of eukaryotic initiation factor 4E-binding 
protein 1. The novel dual PI3K/mTOR inhibitor NVP-
BEZ235, an orally bioavailable imidazoquinoline 
derivative, has entered clinical trials. Moreover in 
both T-ALL cell lines and patient samples. NVP-
BEZ235 was cytotoxic to a panel of T-ALL cell lines as 
determined by MTT assays. NVP-BEZ235 induced cell 
cycle arrest and apoptosis. A dose- and time-dependent 
dephosphorylation of Akt and mTORC1 downstream 
targets was observed after NVP-BEZ235 treatment. 
NVP-BEZ235 targeted the side population of both T-ALL 
cell lines and patient lymphoblasts, which is enriched 
in leukemia initiating cells (LIC), and synergized with 
chemotherapeutic agents (cyclophosphamide, cytarabine, 
dexamethasone) which are used currently for treating 
T-ALL patients. NVP-BEZ235 reduced chemoresistance 
to vincristine induced in Jurkat T cells upon coculturing 
with MS-5 stromal cells, which mimics the bone marrow 
microenvironment. NVP-BEZ235 was cytotoxic to T-ALL 
patient lymphoblasts displaying pathway activation, where 
the drug dephosphorylated eukaryotic initiation factor 
4E-binding protein 1, in contrast rapamycin did not elicit 
such changes. Longitudinal inhibition at two nodes of 
the PI3K/Akt/mTOR network with NVP-BEZ235, either 
alone or in combination with chemotherapeutic drugs, 
may be an efficient treatment of those T-ALLs that have 
aberrant upregulation of this signaling pathway for their 
proliferation and survival [64]. 
The dual PI3K/mTOR inhibitor NVP-BEZ235 
has also been shown recently to synergize with a pan-
histone deacetylase inhibitor in suppressing the growth of 
pancreatic cancer [65]. 
Effective Akt inhibitors have been recently 
developed. The Akt inhibitor MK-2206 has been shown 
to be effective in suppressing the growth of many cancers 
including leukemias. This Akt inhibitor is currently in 
many clinical trials with cancer patients have diverse 
diseases either as a single or combined agent with an 
additional signal transduction inhibitor or  chemo- or 
endocrine therapy [65]. The PI3K/PTEN/Akt/mTORC1 
pathway is frequently upregulated in T-ALL, The effects 
of the novel allosteric Akt inhibitor, MK-2206, on a panel 
of human T-ALL cell lines and primary cells from T-ALL 
patients were examined. MK-2206 decreased cell viability 
by blocking leukemic cells in G0/G1 and induced apoptosis 
as well as autophagy and a concentration-dependent 
dephosphorylation of Akt and its downstream targets, 
GSK-3alpha/beta and FOXO3A. MK-2206 was cytotoxic 
to primary T-ALL cells and importantly induced apoptosis 
in the T-ALL patient cell subset (CD34+, CD4-, CD7-), 
which are enriched in LICs.  Akt inhibition may represent 
a potential therapeutic strategy in T-ALL.
Alkylphospholipids and alkylphosphocholines 
(APCs) are promising antitumor agents, which target 
the plasma membrane and affect multiple signal 
transduction networks including Akt. The therapeutic 
potential of erucylphosphohomocholine (ErPC3), the first 
intravenously applicable APC, on human AML cells was 
determined.  At short (6-12 h) incubation times, ErPC3 
blocked cells in G2/M phase of the cell cycle, whereas, 
at longer incubation times, it decreased survival and 
induced apoptotic cell death. ErPC3 induced JNK 1/2 
activation while stimulating ERK 1/2 dephosphorylation. 
Pharmacological inhibition of caspase-3 or a JNK 1/2 
inhibitor peptide reduced ErPC3 cytotoxicity. Protein 
phosphatase 2A downregulation by siRNA inhibited ERK 
1/2 dephosphorylation and blunted the cytotoxic effects of 
ErPC3. ErPC3 was also cytotoxic to AML primary cells 
and importantly reduced the clonogenic activity of CD34+ 
leukemic cells. ErPC3 treatment induced apoptosis in the 
(CD34+ , CD38(Low/-), CD123+) compartment which is 
enriched in putative LICs. ErPC3 induced cytotoxicity 
on AML blasts which expressed high levels of aldehyde 
dehydrogenase activity and on the side population of 
AML cell lines and blasts in which the LIC populations 
are believed to reside. Thus ErPC3 might be a promising 
therapeutic agent for the treatment of AML patients [66]. 
Advances in Understanding the Pleiotropic 
Effects of mTOR.
The importance of mTOR and its inhibition in 
various conditions, including cancer, diabetes, aging and 
others has been further elucidated. Recently mTOR has 
been shown to be cell cycle regulated [67,68]. mTOR has 
been referred to as the gatekeeper of autophagy. mTOR 
plays important roles in many biological processes, 
including; autophagy [69] energy control [70-72], 
insulin resistance [73], diabetes [74,75], seizures [76,77], 
protein homeostasis [78], regulation of tRNA expression 
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[79,80], cell cycle arrest [81], cell differentiation [82,83], 
cell migration [84,85], follicle development [86], 
DNA damage checkpoint [87], DNA replication stress 
[88],cellular quiescence/senescence [89-107] progeria 
[108], age-related retinal diseases [109], obesity [110], 
stem cells [111], cancer [112,113] , aging [114-134], 
Alzheimer’s disease [135] and Parkinson’s disease [136]. 
mTORC1 is a critical repressor of autophagy, a 
lysosome-dependent degradation pathway which allows 
cells to recycle damaged or unnecessary cytoplasmic 
content, such as lipids, proteins, and organelles [138-156]. 
As a consequence, cells produce metabolic precursors for 
macromolecular biosynthesis or ATP generation. In cancer 
cells, autophagy fulfills a dual role, as it has both tumor-
promoting and tumor-suppressing properties. Functional 
autophagy prevents necrosis and inflammation, which 
can lead to genetic instability. However, autophagy is 
important for tumor progression by providing energy 
through its recycling mechanism during unfavorable 
metabolic circumstances, which frequently occurs in 
certain tumors [138-156]. 
A model was proposed recently by Dr. Michael 
P. Lisanti and colleagues which is called the reverse 
Warburg Effect. This model proposes that the aerobic 
glycolysis occurring in the tumor associated fibroblasts 
and not in the actual epithelial tumor cells [142,146-150]. 
This results in the transfer of high-energy metabolites 
(lactate and pyruvate) to adjacent epithelial cancer cells 
which fuel the cancer cells allowing them to invade and 
metastasize. In addition, oxidative stress generated by the 
cancer cells induces autophagy of the tumor associated 
fibroblasts which the cancer cells then recycle and use 
to fuel their growth. Anti-oxidants (N-acetyl cysteine, 
NAC), quercetin and the anti-diabetes drug metformin) 
or autophagy inhibitors (chloroquine) will suppress 
the destruction of caveolin-1 in stromal fibroblasts and 
inhibit cancer growth. Caveolin-1 is a key protein at the 
cell membrane which serves to organize other important 
signaling molecules into signaling complexes (e.g., Fak, 
Src). Decreased expression of caveolin-1 is associated 
with a poorer prognosis of breast and other cancers.
Autophagy is also important in blood cancers 
[151-153]. Autophagy can be regulated by epigenetic 
mechanisms [154].  Autophagy may also become defective 
in certain drug resistant cells [155]. Defective autophagy 
may be controlled by the p53 rheostat in cancer [156]. 
Clearly autophagy is a very important survival process 
which is regulated in part by mTORC1.
The mTORC1 blocker rapamycin may be useful in 
the treatment of many diseases including HIV and HCV 
infections [157,158].  
Advances in mTOR Kinase Inhibitors.
mTOR kinase inhibitors have been developed and 
evaluated on many diseases including leukemias [159]. 
mTOR is present in two complexes, mTORC1 and 
mTORC2. Both of these complexes play critical roles 
in signal transduction pathways and regulate cell growth 
and many other physiological processes. Rapamycin 
and rapalogs only inhibit (block) mTORC1. Allosteric 
inhibition of mTORC1 by rapamycin had only modest 
effects in T-ALL. ATP-competitive inhibitors specific for 
the mTOR kinase active site have been developed recently. 
The therapeutic potential of active-site mTOR inhibitors 
in suppressing growth in T-ALL cell lines and primary 
samples from T-ALL patients which had activation of 
mTORC1 and mTORC2 was examined. The inhibitors 
affected T-ALL cell viability by inducing G0/G1 cell cycle 
arrest, apoptosis and autophagy. Decreased levels of 
the mTORC2 target Ser 473 Akt were detected as well 
as dephosphorylation of mTORC1 downstream targets. 
Unlike rapamycin, marked inhibition of mRNA translation 
in T-ALL cell lines treated was observed with active-site 
mTOR inhibitors. The mTOR inhibitors synergized with 
both vincristine and the Bcl-2 inhibitor, ABT-263. The 
mTOR inhibitors targeted a putative LIC sub-population 
(CD34+, CD7-, CD4-) in the ALL patient samples. The 
mTOR inhibitors displayed remarkable anti-leukemic 
activity, and could become clinical candidates for T-ALL 
therapy [160]. 
Advances in Targeting the NF-kappaB Pathway.
Targeting the NF-kappaB pathway has been shown 
to be a potential therapeutic approach in leukemia and 
other therapies. The NF-kappaB pathway is regulated in 
part by PI3K/PTEN/Akt/mTOR pathway. The IkappaB 
kinase (IKK)/NF-kappaB axis is required for viability of 
leukemic cells and is a predictor of relapse in T-ALL. It 
turns out that many anticancer agents induce NF-kappaB 
nuclear translocation. This results in activation of NF-
kappaB target genes, which can alter the sensitivity to 
chemotherapeutic drugs. The I-kappaB kinase inhibitor 
is the target of BMS-345541 [161]. The anti-proliferative 
effects of BMS-345541 in three Notch1-mutated T-ALL 
cell lines and in T-ALL primary cells from pediatric 
patients were investigated. BMS-345541 induced 
apoptosis and accumulation of cells in the G 2/M phase 
of the cell cycle. T-ALL cells treated with BMS-345541 
displayed nuclear translocation of FOXO3a as well as 
downstream p21Cip1 expression. FOXO3a subcellular 
re-distribution was independent of AKT and ERK 1/2 
signaling, suggesting that in T-ALL, the loss of FOXO3a 
tumor suppressor function could be due to deregulation 
of IKK. FOXO3a mutations are not frequently found in 
human tumors. Thus therapeutics activating FOXO3a may 
be more effective than others.  BMS-345541 could be used 
alone or in combination with traditional therapies in the 
treatment of T-ALL.
Dehydroxymethyl-epoxyquinomicin (DHMEQ) 
is an inhibitor of NF-kappaB [162] DHMEQ induces 
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apoptosis through reactive oxygen species (ROS) 
production in hepatoma cells. Cox-2 inhibition is an 
additional approach to inhibit hepatoma cell growth [163]. 
Celecoxib can also synergize with the proteasome inhibitor 
MG132  and suppress the growth of hepatocellular 
carcinoma [164]. Subsequently DHMEQ was determined 
to synergize with the Cox-2 inhibitor celecoxib in 
hepatoma cells, again via a ROS-dependent mechanism 
[165]. DHMEQ cooperated with celecoxib (CLX) to 
decrease NF-kappaB DNA binding and inhibited cell 
proliferation more effectively than treatment with these 
single agents alone. DHMEQ-CLX combination resulted 
in ROS production which in turn induced the expression 
of genes involved in endoplasmic reticulum (ER) stress. 
Silencing TRB3 mRNA, which is associated with ER 
stress, significantly decreased DHMEQ-CLX-induced 
cell growth inhibition. The DHMEQ-CLX combined 
treatment was associated with induction of PARP cleavage 
and down-regulation of the anti-apoptotic proteins Bcl-2, 
Mcl-1 and survivin, as well as activated Akt. CD95 and 
CD95 ligand expression increased synergistically in the 
combined treatment, which was reversed in the presence 
of NAC. Knockdown of CD95 mRNA expression 
decreased DHMEQ-CLX-induced growth inhibition in 
HCC cell lines. Thus the DHMEQ-CLX combination 
killed hepatoma cells via ROS production, ER stress 
response and the activation of intrinsic and extrinsic 
apoptotic pathways.
Advances in Targeting Multiple Points in PI3K/
PTEN/Akt/mTOR pathway. 
An emerging concept in cancer therapy is the 
targeting of multiple points in the PI3K/PTEN/Akt/mTOR 
and other pathways. The expression of the PI3K/PTEN/
Akt/mTOR pathway is often upregulated in melanomas. 
The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibited 
melanoma growth regardless of BRAF mutation status. 
Rapamycin enhanced the activity of the dual PI3K/
mTOR inhibitor NVP-BEZ235 in inhibiting the growth 
of melanoma [166]. Furthermore addition of the MEK 
inhibitor AZD6244 synergized with the dual PI3K/mTOR 
inhibitor NVP-BEZ235 in suppressing melanoma growth. 
The effects of targeting different levels of the PI3K/
PTEN/Akt/mTOR pathway has also been examined in 
various leukemias [167]. The efficacy of co-targeting 
of different components of the PI3K/PTEN/Akt/mTOR 
pathway with a novel dual PI3K/Akt inhibitor has been 
investigated in T-ALL. [168]. The dual PI3K/PDK1 
inhibitor NVP-BAG956 was determined in one study to 
exert the most powerful cytotoxic affects against T-ALL 
cell lines and primary patients samples, in comparison 
to a pan class I PI3K inhibitor (GDC-0941), an allosteric 
Akt inhibitor (MK-2206), an mTORC1 allosteric inhibitor 
(RAD-001), or an ATP-competitive mTORC1/mTORC2 
inhibitor (KU63794).
Often signal transduction inhibitors are cytostatic 
as opposed to cytotoxic. This is especially true with 
rapamycin. The effects of combining targeted therapy 
with chemotherapy is an emerging concept and is also 
being examined by clinical trials [169]. The therapeutic 
potential of a combination of temsirolimus [an allosteric 
mTOR complex 1 (mTORC1) inhibitor] with clofarabine, 
a nucleoside analogue with potent inhibitory effects on 
both ribonucleotide reductase and DNA polymerase was 
examined in AML cell lines and clinical specimens. The 
drug combination (CLO-TOR) displayed synergistic 
cytotoxic effects against a panel of AML cell lines and 
in primary cells from AML patients. The CLO-TOR 
treatment induced arrest at the G0/G1 phase of the cell 
cycle, apoptosis, and autophagy. CLO-TOR combination 
was pro-apoptotic in an AML patient blast subset (CD34+, 
CD38-, CD123+), which is enriched in putative LICs. The 
CLO-TOR combination could represent a novel valuable 
treatment for AML patients, also in light of its efficacy 
against LICs.
Activation of Liver Kinase B1/AMP Activated 
Protein Kinase Pathway as an Anti-Cancer 
Therapy. 
The liver kinase B1/AMP activated protein kinase 
(LMPK) pathway has been determined to be a key 
pathway in metabolism (diabetes) as well as cancer and 
other diseases [170]. The LKB1/AMPK network remains 
functional in a wide range of cancers and can be stimulated 
by drugs, such as N,N-dimethylimidodicarbonimidic 
diamide (metformin) or 5-aminoimidazole-4-carboxamide 
1-β-D-ribofuranoside (AICAR). LKB1/AMPK signaling 
induces cell cycle arrest, caspase-dependent apoptosis 
or autophagy in various tumors. Metformin inhibits 
mTORC1-controlled oncogenetic protein translation, 
which does not occur with allosteric mTORC1 inhibitors, 
such as rapamycin and its derivatives. Metformin also 
targets LICs and CICs, the critical target for leukemia 
eradication. Thus the LKB1/AMPK pathway is critically 
involved in regulating proliferation and survival of 
malignant cells. Drugs activating LKB1/AMPK may be 
both a novel and less toxic treatment option for certain 
malignancies [171-174]. 
The effects of metformin against T-ALL cell 
lines and primary samples from T-ALL patients 
displaying mTORC1 activation. Metformin inhibited 
T-ALL cell viability by inducing autophagy and 
apoptosis. Importantly, it was much less toxic against 
proliferating CD4+ T-lymphocytes from healthy donors. 
Dephosphorylation of downstream targets of mTORC1 
were detected. A marked inhibition of mRNA translation 
in T-ALL cells treated with metformin, in contrast such an 
inhibition of translation was not observed after rapamycin 
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treated. Remarkably, metformin targeted the side 
population of T-ALL cell lines as well as a putative LIC 
subpopulation (CD34+, CD7-, CD4-) in primary patient 
samples. Metformin displayed a remarkable anti-leukemic 
activity, which emphasizes future development of LKB1/
AMPK activators as clinical candidates for therapy of 
T-ALL [175]. AMPK has also been shown to be important 
in BCR-ABL-induced CML and AMPK activators may 
prove useful as supplemental drugs for this disease [176]. 
AMPK can also be activated by rapamycin  [177]. 
The plant natural product berberine has recently 
been shown to inhibit the growth of drug resistant breast 
cancer cells whereas the parental drug sensitive line 
was not as growth inhibited [178]. Berberine may also 
target LKB1/AMPK. Breast cancer cells overexpressing 
neutrophil gelatinase associated lipocalin (NGAL) were 
more sensitive to berberine than parental cells which did 
not over express NGAL [178].
Advances in Understanding the p53 Pathway and 
Targeting. 
Both the PI3K/PTEN/Akt/mTOR and Ras/Raf/
MEK/ERK pathways can interact with the p53 pathway at 
various levels. Functional p53 gene status was determined 
to be important in the sensitivity of prostate cancer cells 
to chemotherapeutic drugs, radiation treatment and the 
small molecule MDM2 inhibitor Nutlin 3A. [179]. The 
p53 transcription factor is a critical element in the ability 
of the cell to regulate the cell cycle and its response to 
DNA damage. Mutations within the DNA-binding 
domain of p53 are common in human cancers and allow 
the formation of tetramers; however, these alterations 
prevent this protein complex from associating with 
appropriate target gene promoters. The effects of p53 
functionality in prostate cancer cells that harbored WT 
or mutant forms of the protein in response to commonly 
used chemotherapeutic drugs were examined. The 
androgen receptor positive 22Rv-1 and LNCaP prostate 
cancer cell lines carry WT p53 and were demonstrated 
to have a decrease in chemotherapeutic drug sensitivity 
when transfected with a dominant-negative (DN) p53 
gene. Conversely, expression of a WT p53 gene in the 
p53-mutated and more advanced DU145 prostate cancer 
cell line significantly increased its overall sensitivity to 
anti-neoplastic drugs. Analysis of colony formation in 
soft agar revealed that the functional status of p53 in each 
cell line altered the ability to proliferate in an anchorage-
independent fashion. Prostate cancer colony growth 
was more prevalent when p53 transcriptional activity 
was decreased, whereas growth was more limited in the 
presence of functional p53. Thus the functional status of 
the tumor suppressor p53 is important in the progression 
of prostate cancer and dictates the overall effectiveness a 
given drug would have on disease treatment.
p53 has also been shown to be a target for lowering 
associated toxicity of normal cells after chemotherapy. 
The protection of normal cells from cell cycle-specific 
chemotherapeutic agents such as mitotic inhibitors (MI) 
was examined after a 3-day exposure to MI (paclitaxel and 
nocodazole) by colony formation. In three normal human 
cell types with WT-p53 (RPE, NKE, WI-38t cells) but 
not in cancer cells with mutant p53, pre-treatment with 
Nutlin-3a, caused G1 and/or G2 arrest, thus preventing 
lethal mitotic arrest normally induced by MIs and 
allowing normal cells to recover after removal of the MIs. 
Rapamycin potentiated the protective effects of Nutlin-3a 
in the p53-WT cells. Also, a combination of rapamycin 
and metformin, induced G1 and G2 arrest selectively in 
p53-WT cells and thereby protected them from the MIs. A 
combination of metformin and rapamycin also protected 
p53-WT cells in low glucose conditions, whereas it was 
cytotoxic for p53 mutant cells. A rational combination of 
metformin and rapamycin may potentiate chemotherapy 
with MIs, while protecting normal cells thus therapy-
induced toxicities [180-181]. 
Advances in Roles of Androgen Receptor, Beta-
Catenin, and Akt in Androgen Responsiveness of 
Prostate Cancer. 
The effects of silencing androgen receptor (AR), 
beta-catenin and Akt expression in prostate cancer growth 
and migration were examined [182]. The mechanisms 
responsible for the conversion of prostate cancer from 
androgen-sensitive (AS) to androgen-insensitive (AI) are 
not well understood. AR signaling involves cross-talk 
with the other signaling pathways, and other proteins, 
such as beta-catenin. To further elucidate some of the 
biochemical changes that occur during the switch from 
AS to AI form, AR, Akt and β-catenin expression were 
knocked-down with respective siRNAs. Treatment of AR+ 
LNCaP prostate cells with siRNA for AR significantly 
reduced proliferation (45-70%), expression of nuclear 
β-catenin, cyclin-D1, cyclin-G1, c-Myc as well as 
activity of metalloproteinases (MMPs) -2,-7,-9 and cell 
migration. After longer periods of  AR silencing (over 72 
hrs) in LNCaP cells, elevated levels of activated Akt were 
detected and enhanced proliferation as well as expression 
of nuclear beta-catenin, cyclin-D1, c-Myc and activity of 
MMPs were observed. Such effects were not observed in 
either AI, AR-, PC-3 or DU145 cells. However, silencing 
of Akt and /or beta-catenin in those as well as in AS, AR+ 
LNCaP cells led to decreased proliferation and migration. 
These studies indicate that either AR or Akt signaling 
prevails, depending on their initial androgen sensitivity 
as well as its availability. In AI prostate cancer cells, Akt 
takes over the role of AR and more effectively contributes 
through the same signaling molecule, beta-catenin, to 
AI cancer progression. Thus Akt can be a key target in 
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prostate cancer.
Advances in NO-Modified Drugs and Inhibitors. 
Recently the effect on nitric oxide (NO)-modified 
inhibitors and drugs has been examined in various 
cancer settings [183-185]. The NO-modified form of 
HIV protease inhibitor Saquinavir (Saq) is a potent 
antitumoral agent efficient against numerous tumor cell 
lines in vitro and in vivo. Saq-NO was determined to 
sensitize certain types of cells to tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL)-mediated cell 
death. Saq-NO inhibited both the growth of LNCaP cells 
in vitro and in xenograft models. Suppression of tumor 
growth was accompanied with cell cycle arrest in G0/G1 
phase. Permanent abrogation of S6 phosphorylation was 
observed. Diminished S6 phosphorylation was associated 
with re-established sensitivity to TRAIL and reduction 
of X-linked inhibitor of apoptosis protein (XIAP). NO 
modification of Saq led to a new chemical entity with 
stronger and more pleiotropic antitumor activity than the 
parental drug. 
The effects of the NO-modified anti-inflammatory 
drug (S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid 
(VGX-1027) named GIT-27NO or the NO-modified 
antiviral drug saquinavir (Saq) named Saq-NO were 
examined on colon cancer cell lines, murine CT26CL25 
and human HCT116. Both agents suppressed the growth 
of colon cancer cells in vitro. The efficacy of the drugs 
was evaluated in vivo in BALB/c mice injected with 
CT26CL25 cells. Both agents suppressed reduced 
tumor volume in syngeneic BALB/c mice. However, 
their mechanisms of action were different as GIT-27NO 
released larger amounts of nitrite than Saq-NO in vitro 
and its antitumor action depended on the intracellular 
NO release. In contrast, Saq-NO released barely 
detectable amounts of NO and its antitumor action was 
NO-independent. Cotreatment with an NO-peroxynitrite 
scavenger revealed that GIT-27NO but not Saq-NO 
acts through peroxynitrite-mediated cell destruction. 
GIT-27NO predominately induced proapoptotic signals 
followed by caspase-dependent apoptosis. While Saq-
NO blocked cell proliferation, changed their adhesive, 
migratory, and invasive properties, and decreased their 
metastatic potential in vivo. In conclusion, differences in 
NO release and oxidative stress generation between GIT-
27NO and Saq-NO resulted in different mechanisms that 
resulted in cell death [186]. 
Advances in Elucidating Role of NGAL in Cancer. 
Neutrophil gelatinase associated lipocalin (NGAL 
aka lipocalin-2 or siderocalin) has been shown to play 
diverse roles, from stabilizing matrix matalloproteinase 
(MMP-9) to combating bacterial infection by binding 
bacterial siderophores and preventing bacterial iron 
sequestration to roles in cancer invasion, EMT, and 
metastasis [187]. NGAL is believed to play roles in 
promoting survival, growth, invasion and metastasis. 
In addition NGAL may also have roles in sequestration 
of iron resulting in cell survival and tumorigeneis. 
Upregulated NGAL expression in often upregulated in 
advanced tumors and is easily detected in urine. Clearly 
NGAL may represent an important marker for certain 
cancers.
Recently the role of NGAL in sensitivity to targeted 
therapy has been investigated in breast cancer cells. 
Ecotopic expression of NGAL does not increase the 
resistance of cancer cells to doxorubicin [188]. In contrast, 
ectopic expression of NGAL did alter the sensitivity of 
MCF-7 breast cancer cells to targeted therapy [178] 
MCF-7/NGAL were more sensitive to EGFR, Bcl-2 
and calmodulin kinase inhibitors as well as the natural 
plant product berberine than MCF-7 cells infected with 
the empty retroviral vector pLXSN. These results are 
important as the expression of NGAL is often detected at 
elevated levels after chemotherapy [189]. Furthermore the 
expression of NGAL increases in more advanced cancers.
SUMMARY
In this review, we have discussed some of the 
recent advances in targeting certain signal transduction 
pathways. Although there have been many advances in 
our understanding of other key pathways involved in 
cancer such as Wnt/beta-catenin [190], Notch [191] and 
hedgehog [192], we have primarily focused on the Ras/
Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways due 
to space considerations. Clearly as we learn more about 
these pathways, we find that they have not only complex 
interactions with other pathways, but the importance of 
genetics and biochemistry in the sensitivity and resistance 
to targeted therapy. Further elucidation of these and other 
signaling pathways may allow more effective therapies to 
be developed for cancer and other diseases.
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